PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$111.44
as of July 02, 2026 -
YTD RETURNS8.96%
as of July 02, 2026 -
Total Net Assets$923.64M
as of July 02, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 4.42 | 5.83 | 6.97 | 27.15 | 13.83 | 10.55 | 8.46 | 10.15 |
| PPH (Market Price) | 4.40 | 6.13 | 6.86 | 27.12 | 13.83 | 10.52 | 8.46 | 10.22 |
| MVIS US Listed Pharmaceutical 25 Index | 4.38 | 5.74 | 6.73 | 26.87 | 13.35 | 10.15 | 8.20 | 9.95 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 4.42 | 5.83 | 6.97 | 27.15 | 13.83 | 10.55 | 8.46 | 10.15 |
| PPH (Market Price) | 4.40 | 6.13 | 6.86 | 27.12 | 13.83 | 10.52 | 8.46 | 10.22 |
| MVIS US Listed Pharmaceutical 25 Index | 4.38 | 5.74 | 6.73 | 26.87 | 13.35 | 10.15 | 8.20 | 9.95 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 07/02/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
20.10 |
195,764,838 |
|
NVS |
Novartis Ag |
10.64 |
103,653,896 |
|
MRK |
Merck & Co Inc |
9.75 |
94,910,085 |
|
NVO |
Novo Nordisk A/S |
5.54 |
53,969,278 |
|
ABBV |
Abbvie Inc |
4.66 |
45,379,187 |
|
PFE |
Pfizer Inc |
4.47 |
43,523,169 |
|
GSK |
Gsk Plc |
4.44 |
43,239,067 |
|
JNJ |
Johnson & Johnson |
4.43 |
43,123,041 |
|
BMY |
Bristol-Myers Squibb Co |
4.43 |
43,108,801 |
|
AZN |
Astrazeneca Plc |
4.38 |
42,637,738 |
|
MCK |
Mckesson Corp |
4.21 |
41,015,767 |
|
SNY |
Sanofi Sa/France |
3.98 |
38,731,352 |
|
COR |
Cencora Inc |
3.45 |
33,620,972 |
|
HLN |
Haleon Plc |
3.19 |
31,103,465 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
3.07 |
29,893,558 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
2.95 |
28,725,132 |
|
ZTS |
Zoetis Inc |
2.14 |
20,886,703 |
|
VTRS |
Viatris Inc |
1.13 |
11,010,494 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.07 |
10,439,020 |
|
AXSM |
Axsome Therapeutics Inc |
0.75 |
7,326,368 |
|
CORT |
Corcept Therapeutics Inc |
0.51 |
4,998,717 |
|
ELAN |
Elanco Animal Health Inc |
0.35 |
3,430,575 |
|
OGN |
Organon & Co |
0.23 |
2,192,282 |
|
BHC |
Bausch Health Cos Inc |
0.10 |
930,226 |
|
PRGO |
Perrigo Co Plc |
0.06 |
609,362 |
|
-USD CASH- |
-- |
0.09 |
845,534 |
|
-- |
Other/Cash |
-0.13 |
-1,275,498 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 06/30/2026
-
Sector
% of Net Assets
Country Weightings (%) as at 06/30/2026
-
Country
% of Net Assets
Fees
Distributions
as of 07/02/2026
Quarterly
1.90%
2.24%
1.95%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency